Prostate specific membrane antigen imaging (PSMA)
Breaking News! What you need to know about the newly approved 68Ga-PSMA-11 PET agent for prostate cancer
Prostate-specific membrane antigen (PSMA) imaging is a nuclear medicine exam using positron emission tomography (PET) to detect prostate cancer. This scan is investigational and has not yet been approved by the U.S. Food and Drug Administration.
PSMA PET is very sensitive for detecting prostate cancer, with accumulating evidence suggesting it is superior to conventional imaging tests such as CT scans or bone scans. There are several agents currently being studied at academic institutions, including those labeled with gallium 68 (68Ga) and others with fluciclovine (18F).
Currently, the PSMA PET scan is being studied in two patient populations:
While early trials have shown promising results, further studies are needed to confirm long-term improvement in outcomes as a result of this test.
Figure 1. Examples of normal (left) and abnormal 68Ga-PSMA-11 scans. Sites of metastatic disease are indicated in the heading and with arrows.
For more information see the following:
Information from pioneers in the field, Dr. Baum and his team in Bad Berka, Germany.
A look at the use of PSMA agents in prostate cancer management:
A discussion between a radiologist, a medical oncologist, and a urologist on how PSMA scans influence patient management: